Chembio Diagnostics Inc. (NASDAQ:CEMI) issued its quarterly earnings data on Thursday. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.02. Chembio Diagnostics had a negative return on equity of 24.17% and a negative net margin of 45.99%. The business earned $3.75 million during the quarter, compared to the consensus estimate of $3.76 million.

Shares of Chembio Diagnostics (NASDAQ:CEMI) opened at 6.85 on Thursday. The stock’s market cap is $82.10 million. Chembio Diagnostics has a 12-month low of $4.03 and a 12-month high of $9.40. The stock has a 50 day moving average price of $7.09 and a 200-day moving average price of $7.52.

Earnings History for Chembio Diagnostics (NASDAQ:CEMI)

Separately, Benchmark Co. reissued a “buy” rating and set a $9.00 price objective (down from $10.00) on shares of Chembio Diagnostics in a research note on Sunday, August 14th.

Chembio Diagnostics Company Profile

Chembio Diagnostics, Inc (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc, develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies.

5 Day Chart for NASDAQ:CEMI

Receive News & Stock Ratings for Chembio Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics Inc. and related stocks with our FREE daily email newsletter.